Australian Bill Brings Further Price Cuts But Promise Of More New Drug Listings
Executive Summary
A new bill just approved in Australia will introduce further price cuts in order to reap savings on the pharmaceutical bill, which will partly be used to fund the reimbursement listing of new drugs. The pharmaceutical industry will also benefit from a more predictable pricing environment, at least until 2022.
You may also be interested in...
Stability At Last For Drug Innovators And Pricing In Australia
The Australian government has promised not to implement any new therapeutic groups under the Pharmaceutical Benefits Scheme for the next five years, nor will it introduce any new pricing reforms without consulting the innovative drug industry first.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.